Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC with D2 Resection for Advanced Gastric Cancer
NCT02960061Phase 3Unknown
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Nov 2016
- Primary completion
- Dec 2019
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Paclitaxel Micelles for Injection in gastric cancer (GC) (2 arms), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Overall Survival at 5 years. Status: unknown.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02960061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960061.